Loading stock data…
$12.03-0.58 (-4.60%)
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics.
Arcturus Therapeutics Holdings Inc. in the Healthcare sector is trading at $12.03 with a market capitalization of $450M. Wall Street consensus targets $23.80 (10 analysts), implying a +97.8% move over the next 12 months. The stock is currently 50% below its 52-week high of $24.17, remaining 37.8% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $880,000↑ | $610,000↓ | $3.08M↓ | $14.15M↓ | $24.51M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$25.55M↑ | -$28.93M↑ | -$31.31M↓ | -$16.51M↓ | -$11.62M |
| Net Income | -$23.79M↑ | -$26.96M↑ | -$29.08M↓ | -$13.45M↓ | -$9.18M |
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a li...